# KEYNOTE-867 (NCT03924869)

> Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03924869
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Stereotactic Body Radiotherapy (SBRT); Pembrolizumab; Placebo
- Enrollment: 448
- Primary outcome: Event-free Survival (EFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-867-nct03924869